Related Experiment Video
Updated: Jul 27, 2025
Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer
Published on: July 28, 2010
[Molecular pathology of colorectal cancer]
Christine Woischke1, Marlies Michl2,3, Jens Neumann4
1Pathologisches Institut, Medizinische Fakultät, Ludwig-Maximilians-Universität München, Thalkirchner Str. 36, 80337, München, Deutschland.
Abstract:
In recent years, the treatment of colorectal carcinoma has experienced increasing individualization. In addition to RAS and BRAF mutational status that is firmly established in routine diagnostics, new therapeutic options evolved based on MSI and HER2 status as well as primary tumour localization. Offering the best targeted options in therapy requires new evidence-based decision-making algorithms regarding timing and scope of molecular pathological diagnostics in order for patients to receive an optimized therapy according to current treatment guidelines. New targeted therapies, some of which are about to be approved and for which pathology has to provide new molecular pathological biomarkers, will also play an increasingly important role in the future.
Insights
Personalized colorectal cancer treatment now includes MSI, HER2 status, and tumor location. Molecular diagnostics are crucial for guiding optimal, evidence-based therapy and preparing for new targeted treatments.
Area of Science:
- Oncology
- Molecular Pathology
- Cancer Diagnostics
Context:
- Colorectal carcinoma treatment is increasingly individualized.
- Established biomarkers include RAS and BRAF mutational status.
- Emerging biomarkers include microsatellite instability (MSI) and HER2 status, alongside primary tumor localization.
Purpose:
- To outline the evolving landscape of molecular diagnostics in colorectal cancer.
- To emphasize the need for evidence-based algorithms for molecular pathological diagnostics.
- To align diagnostic strategies with current treatment guidelines and emerging targeted therapies.
Summary:
- Recent advancements in colorectal cancer treatment emphasize personalization beyond RAS/BRAF status.
- Microsatellite instability (MSI), HER2 status, and primary tumor location are now key factors.
- Optimized patient therapy relies on timely and comprehensive molecular pathological diagnostics.
- Future treatment will incorporate new targeted therapies requiring novel molecular biomarkers.
Impact:
- Facilitates optimized, guideline-adherent therapy selection for colorectal cancer patients.
- Supports the integration of new molecular biomarkers into routine pathological diagnostics.
- Enhances the potential of emerging targeted therapies by ensuring appropriate patient stratification.
